Breast Cancer

Recent data suggest that the use of blood thinners may be unnecessary in women with a history of recurrent pregnancy loss and inherited thrombophilia, according to researchers.

This year’s San Antonio Breast Cancer Symposium spotlighted practice-changing research in several subtypes.

Long travel times to facilities offering mammography substantially limited accessibility to breast cancer screening, particularly for women living in rural areas, according to data published in the Journal of the National Cancer Institute.

SAN ANTONIO — The addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy significantly improved outcomes among patients with triple-negative breast cancer, according to study results.

SAN ANTONIO — Sacituzumab govitecan prolonged survival compared with physician’s choice of therapy among patients with heavily pretreated breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

National Cancer Institute Director Monica M. Bertagnolli, MD, FACS, FASCO, announced that she has been diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer.

Results presented from TROPiCS-02 showed that sacituzumab govitecan was effective in a subset of patients with breast cancer regardless of Trop-2 expression level, according to data presented at San Antonio Breast Cancer Symposium.

Adjuvant paclitaxel and trastuzumab continued to appear effective after 10 years of follow up among patients with small node-negative, HER2-positive breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — A symptom pattern model predicted risk for immune-related adverse events among women with early-stage, high-risk breast cancer, according to an analysis of the phase 2 I-SPY2 trial presented at San Antonio Breast Cancer Symposium.